Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Closed 06-25 16:00:00 EDT

327.86

+18.92

+6.12%

盘后327.86

+0.000.00%

19:43 EDT

High328.68	Low304.97	Vol864.25K
Open306.03	D1 Closing308.94	Amplitude7.67%
Mkt Cap9.13B	Tradable Cap8.45B	Total Shares27.85M
T/O279.16M	T/O Rate3.35%	Tradable Shares25.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":327.86,"timestamp":1782417600000,"preClose":308.94,"halted":0,"volume":864246,"hourTrading":{"tag":"盘后","latestPrice":327.86,"preClose":327.86,"latestTime":"19:43 EDT","volume":94741,"amount":31061492.2517,"timestamp":1782431002480,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.061241665048229484,"floatShares":25778700,"shares":27850833,"eps":-13.34879,"marketStatus":"Closed","change":18.92,"latestTime":"06-25 16:00:00 EDT","open":306.03,"high":328.68,"low":304.97,"amount":279155122.40304,"amplitude":0.076746,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.34879,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782460800000},"marketStatusCode":5,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":308.94,"preHourTrading":{"tag":"盘前","latestPrice":308,"preClose":308.94,"latestTime":"04:00 EDT","volume":2,"amount":616,"timestamp":1782374414839,"change":-0.94,"changeRate":-0.003043,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":327.86,"preClose":327.86,"latestTime":"19:43 EDT","volume":94741,"amount":31061492.2517,"timestamp":1782431002480,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.480354,"impliedVol":0.5997,"impliedVolPercentile":0.0239},"requestUrl":"/m/hq/s/PRAX","defaultTab":"news","newsList":[{"id":"2645812834","title":"Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645812834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645812834?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:21","pubTimestamp":1782220869,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Praxis Precision Med...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-revolution-medicines-rvmd-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-revolution-medicines-rvmd-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","RVMD","IE00B2B36J28.USD","LU0320765992.SGD","IE0002141913.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4139","LU0109394709.USD","IE00BJJMRZ35.SGD","PRAX","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024421","title":"Praxis wins FDA breakthrough therapy tag for elsunersen in SCN2A-DEE seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024421","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024421?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:07","pubTimestamp":1782130044,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines won FDA Breakthrough Therapy designation for elsunersen to treat seizures tied to SCN2A gain-of-function developmental epileptic encephalopathy.The designation follows results already presented from a small randomized, sham-controlled early-stage study showing a clinically meaningful drop in seizure burden.Benefits appeared durable in an extension phase, supporting a potential disease-targeted approach in a setting with limited treatment options.A pivotal EMBRAVE3 registrational study is enrolling on a streamlined single-arm design, with patients treated for 24 weeks followed by a 24-week extension.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL66WfTy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","PRAX","IE0002141913.USD","LU0320765992.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645502454","title":"Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated With Scn2a Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2645502454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645502454?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA6PK4ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B2B36J28.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","PRAX","LU0109394709.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645246750","title":"Praxis Precision Medicines - Elsunersen Well-Tolerated With No Drug-Related Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2645246750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645246750?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA6PK4ZX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","IE0002141913.USD","BK4139","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","PRAX","IE0009355771.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024667","title":"Praxis Precision Medicines - Elsunersen Shows 77% Sham-Adj Reduction in Monthly Seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024667?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA6PK4ZX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","IE0009355771.USD","BK4139","LU0109394709.USD","PRAX","LU0889565916.HKD","IE00B2B36J28.USD","IE0002141913.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645302473","title":"Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2645302473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645302473?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129600,"startTime":"0","endTime":"0","summary":"The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen  Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315249/0/en/Praxis-Precision-Medicines-Receives-FDA-Breakthrough-Therapy-Designation-for-Elsunersen-for-the-Treatment-of-Seizures-Associated-with-SCN2A-Developmental-and-Epileptic-Encephalopat.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4135","LU0109394709.USD","ASO","BK4585","IE0009354923.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LABU","IE0002141913.USD","IE0009355771.USD","BK4139","CNS","PRAX","LU0889565916.HKD","BK4588","IE00BJT1NW94.SGD","BK4200","IE00BFTCPJ56.SGD","ODD","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106982805","title":"Movement Alert｜Praxis Precision Medicines Rises 5.02% in Regular Trading, Trading at $283.05","url":"https://stock-news.laohu8.com/highlight/detail?id=1106982805","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106982805?lang=en_us&edition=fundamental","pubTime":"2026-06-19 02:32","pubTimestamp":1781807546,"startTime":"0","endTime":"0","summary":"On June 19, Praxis Precision Medicines rose 5.02% in regular trading, trading at $283.05 USD/share, with Turnover of $57.06 million.Within the Biotechnology sector where Praxis Precision Medicines...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644084575","title":"Praxis Precision Medicines' Share Pullback Represents Good Entry Point, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644084575","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644084575?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:38","pubTimestamp":1781793514,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines' (PRAX) recent share pullback provides investors an \"interesting entry point\" as the reward/risk proposition of over $7.8 billion in revenue potential by 2035 is attractive,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","IE0002141913.USD","IE0009355771.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","PRAX","IE00BJT1NW94.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702117","title":"RBC Initiates Praxis Precision Medicines at Outperform, Speculative Risk With $449 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702117","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702117?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:27","pubTimestamp":1781778455,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $612.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154252010","title":"Movement Alert｜Praxis Precision Medicines Rises 5.29% in Regular Trading, Trading at $271.2","url":"https://stock-news.laohu8.com/highlight/detail?id=1154252010","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154252010?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:56","pubTimestamp":1781704599,"startTime":"0","endTime":"0","summary":"On June 17, Praxis Precision Medicines rose 5.29% in regular trading, trading at $271.2/share, with Turnover of $22.19 million.Within the Biotechnology sector where Praxis Precision Medicines...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643774132","title":"Praxis Precision Medicines (PRAX) Stock After Vormatrigine POWER1 Miss And POWER2 Pause How Does Valuation Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2643774132","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643774132?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:22","pubTimestamp":1781518941,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) recently reported mixed Phase 2/3 POWER1 results for its epilepsy candidate vormatrigine. The trial missed its primary endpoint but showed dose dependent secondary benefits and acceptable tolerability.\nSee our latest analysis for Praxis Precision Medicines.\nThe latest vormatrigine update appears to have sharpened near term risk perceptions, with the share price down 22.18% over the past 30 days and 12.13% over 90 days, even as the 1 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-stock-after-vormatrigine-pow","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-stock-after-vormatrigine-pow","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","PRAX","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE0002141913.USD","IE00B2B36J28.USD","LU0109394709.USD","IE0009355771.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643023215","title":"Praxis Precision Medicines Shareholders Back Directors and Governance","url":"https://stock-news.laohu8.com/highlight/detail?id=2643023215","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643023215?lang=en_us&edition=fundamental","pubTime":"2026-06-13 07:33","pubTimestamp":1781307192,"startTime":"0","endTime":"0","summary":"An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On June 10, 2026, Praxis Precision Medicines, Inc. held its 2026 Annu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-precision-medicines-shareholders-back-directors-and-governance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-precision-medicines-shareholders-back-directors-and-governance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PRAX","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0109394709.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218088","title":"Praxis Precision Medicines shareholders elect three Class III directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218088","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218088?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:47","pubTimestamp":1781297226,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines held its annual shareholder meeting on June 10, 2026.Shareholders selected Gregory Norden, Marcio Souza, William Young as Class III directors for terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDLbQcGNc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","BK4139","LU0889565916.HKD","IE00BJT1NW94.SGD","PRAX","IE00B4R5TH58.HKD","IE0002141913.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120935768","title":"Movement Alert｜Praxis Precision Medicines Rises 5.81% in Regular Trading, Trading at $262.38","url":"https://stock-news.laohu8.com/highlight/detail?id=1120935768","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120935768?lang=en_us&edition=fundamental","pubTime":"2026-06-12 22:02","pubTimestamp":1781272958,"startTime":"0","endTime":"0","summary":"On June 12, Praxis Precision Medicines rose 5.81% in regular trading, trading at $262.38/share, with Turnover of $9.893 million.Within the Biotechnology sector where Praxis Precision Medicines...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642256659","title":"Praxis Precision Medicines (PRAX) Is Down 6.3% After Mixed Vormatrigine POWER1 Data Release - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2642256659","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642256659?lang=en_us&edition=fundamental","pubTime":"2026-06-12 09:37","pubTimestamp":1781228257,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines recently reported that its Phase 2/3 POWER1 trial of vormatrigine in adults with focal onset seizures did not meet the primary endpoint, although secondary measures showed a 50% responder rate, stronger seizure reduction at the higher 30 mg dose, and generally favorable tolerability.\nDespite pausing enrollment in the companion POWER2 study to reassess the program, the high proportion of patients opting into ongoing open-label treatment suggests clinicians and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-is-down-63-after-mixed-vorma","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-is-down-63-after-mixed-vorma","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PRAX","IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4139","IE0009355771.USD","LU0889565916.HKD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122813404","title":"Movement Alert｜Praxis Precision Medicines Rises 5.02% in Regular Trading, Trading at $249.57","url":"https://stock-news.laohu8.com/highlight/detail?id=1122813404","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122813404?lang=en_us&edition=fundamental","pubTime":"2026-06-12 01:55","pubTimestamp":1781200543,"startTime":"0","endTime":"0","summary":"On June 12, Praxis Precision Medicines rose 5.02% in regular trading, trading at $249.57/share, with turnover of $48.332 million.Within the Biotechnology sector where Praxis Precision Medicines...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641748526","title":"Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641748526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641748526?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:40","pubTimestamp":1780915221,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Amylyx Pharmaceut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-amylyx-pharmaceuticals-inc-amlx-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-amylyx-pharmaceuticals-inc-amlx-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","XBI","LU0128526141.USD","IE00B4R5TH58.HKD","PRAX","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4581","BK4588","BK4585","IE0009355771.USD","BK4137","LU0029874061.USD","XLV","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","HCSG","CGEM","LABU","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641164081","title":"Praxis Precision Medicines to present at Goldman Sachs Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2641164081","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641164081?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:01","pubTimestamp":1780603308,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines will present a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.The presentation is scheduled for 8:00 a.m. ET in Miami, Florida.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLb2G6wx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2237438978.USD","LU2471134523.USD","IE0034235188.USD","GSX","IE00B19Z3B42.SGD","LU1868836757.USD","IE00BKPKM429.USD","LU0942090050.USD","IE00BJJMRZ35.SGD","LU1868837300.USD","LU2471134796.USD","BK4127","IE0009355771.USD","LU0061475181.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","LU2210149790.SGD","LU1668664300.SGD","BK4504","LU0106831901.USD","IE00BSNM7G36.USD","LU2471134952.CNY","PRAX","LU2237443382.USD","IE00BFXG1179.USD","LU0889565916.HKD","SG9999014005.SGD","IE00B2B36J28.USD","IE00B19Z3581.USD","LU1791807156.HKD","LU2237443549.SGD","BK4588","NDAQ","LU2237443465.HKD","LU0742534661.SGD","IE00B3QW5Z07.USD","LU0868494708.USD","LU2095319765.USD","LU0320765992.SGD","LU2750360997.AUD","IE0002141913.USD","BK4533","LU0096364046.USD","BK4550","LU1804176565.USD","SG9999014013.SGD","LU0345770993.USD","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149686683","title":"Movement Alert｜Praxis Precision Medicines Falls 5.17% in Regular Trading, Continued Fallout from Core Epilepsy Trial Primary Endpoint Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1149686683","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149686683?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:30","pubTimestamp":1780583441,"startTime":"0","endTime":"0","summary":"On June 4, Praxis Precision Medicines declined 5.17% in regular trading, trading at $272.06/share, with trading volume of $65.41 million. The stock continues to face selling pressure following the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111946657","title":"Movement Alert｜Praxis Precision Medicines Rises 5.31% in Regular Trading, Positive Secondary Endpoint Data Drives Rebound After Primary Endpoint Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=1111946657","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111946657?lang=en_us&edition=fundamental","pubTime":"2026-06-03 22:32","pubTimestamp":1780497120,"startTime":"0","endTime":"0","summary":"On June 3, Praxis Precision Medicines rose 5.31% in regular trading, trading at $271.78/share, with trading volume of $43.23 million.The rebound follows a sharp 15.36% intraday decline after the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.1442},{"period":"1month","weight":-0.1008},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1487},{"period":"1year","weight":6.0278},{"period":"ytd","weight":0.0482}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0166},{"period":"3month","weight":0.1366},{"period":"6month","weight":0.0622},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0753}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166549},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.160217},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.017086},{"month":5,"riseRate":0.5,"avgChangeRate":-0.087139},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.098191},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction